This study is for patients with brain cancer. This study is being done to see if by using stereotactic radiosurgery can reduce symptoms and lower the chance of the cancer growing compared to the ususal radiotherapy.

This study is for patients receiving treatment for cancer that may cause side effects of nausea and vomiting. The purpose of this study is to see if olanzapine given in combination with other standard drugs, is still as effective without using the fosaprepitant.

This study is for men and women with glioblastoma. The purpose is to see if we can lower the chance of memory loss by adding the drug Ramipirl to the usual chemoradiation treatment.

Subjects are being asked to volunteer for a research study because they have their first anaplastic astrocytoma (AA) tumor progression (worsening) or recurrence.

The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Eflornithine is an experimental drug that the United States Food and Drug Administration (FDA) has not approved it for use by the general public. Lomustine has been approved by the FDA in the United States for this patient population.